| 1. KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation.
Grab Sources Here: CTXR Presentation. -----
And as I mentioned above, there are 5 potential catalysts we're focused on for (Nasdaq: CTXR) at the moment. Check them out:
#1. CTXR Potential Catalyst - A Low Float Could Create A Volatility Storm Quickly.
According to info from the Yahoo Finance website, CTXR has a relatively low float.
In fact, the website reports this profile to have approximately 16.52Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If positive company news appears towards the end of 2025, could it provide a breakout spark when paired with this volatility potential? -----
#2. CTXR Potential Catalyst - Final Preparations Are In Process For A U.S. LYMPHIR Launch In 2H 2025.
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), are nearing completion. The Company believes it is now operationally positioned to transition from a development-stage enterprise to a fully integrated commercial organization, with all major launch-enabling activities underway. Final preparations are in process for a U.S. launch of LYMPHIR in the second half of 2025.
"We've made steady and meaningful progress toward commercialization over the past several months," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. "With our supply chain secured, market access supported, and no anticipated impediments to reimbursement, we are encouraged by the momentum we've built. These efforts are pivotal as we transition into a commercial-stage company and believe the planned 2025 launch of LYMPHIR has the potential to be an important inflection point for both the company and the CTCL community," added Mazur.
...
Read the full article here. -----
#3. CTXR Potential Catalyst - The Company's Subsidiary Deploys An Innovative AI Platform Ahead Of LYMPHIR's Anticipated Launch.
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
Proprietary model informs targeted sales and marketing strategies with feedback loop that augments precision and impact of targeting and engagement
CRANFORD, N.J., Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has deployed an innovative AI platform to support its commercial team with advanced data analytics and insights ahead of the anticipated launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL). The platform was developed to strengthen decision-making, refine targeting, and enhance the efficiency of its salesforce by supporting timely, data-informed engagement with healthcare providers.
The proprietary system uses company-defined criteria to identify patterns in treatment and diagnosis, enabling our commercial team to immediately target prescribers whose patients may benefit from LYMPHIR. The platform uses machine learning to continuously refine its ability to identify potential LYMPHIR candidates and allow the commercial team to support more informed patient care.
"We look forward to having this innovative AI platform amplify the precision and impact of our experienced commercial and marketing teams. This proprietary platform is designed to augment the clinical expertise and experience of our salesforce. It is a tool that enhances how we connect science, clinical need and patient access in a more intelligent and scalable way," stated Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma.
...
Read the full article here. -----
#4. CTXR Potential Catalyst - A Distribution Expansion Agreement Could Prove Fruitful As Commercialization Nears.
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™
CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the execution of a distribution services agreement with Cencora (formerly AmerisourceBergen), a global pharmaceutical services company. This agreement marks another significant step forward in the Company's commercial launch strategy for LYMPHIR (denileukin diftitox-cxdl), its FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
This new agreement expands Citius Oncology's commercial distribution network, providing additional access and product availability upon launch. The agreement with Cencora, a leader in specialty pharmaceutical distribution and services, builds on a previously announced distribution services agreement to support long-term scalability and market reach of LYMPHIR.
"As we move closer to the U.S. market introduction of LYMPHIR, we remain focused on disciplined execution across all key commercial readiness activities," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. "Our agreement with Cencora adds further depth to our distribution strategy and strengthens our ability to deliver LYMPHIR to treatment centers across the country. These foundational partnerships demonstrate our ongoing commitment to building a launch platform that supports near-term revenue and long-term shareholder value."
Under the terms of the agreement, Cencora will serve as a wholesale distributor for LYMPHIR, providing specialty distribution services to facilitate product availability across its distribution network.
Read the full article here. -----
#5. CTXR Potential Catalyst - A Distribution Services Agreement With Cardinal Health Marks A Key Step Forward Towards Commercialization.
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma
CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH), a leading provider of pharmaceutical and specialty pharmaceutical distribution services in the United States.
This agreement is designed to help provide access to LYMPHIR™ (denileukin diftitox-cxdl), an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in support of its anticipated U.S. commercial launch.
"This agreement marks a key step forward in our launch readiness efforts," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. "Cardinal Health's proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network."
Under the agreement, Cardinal Health will serve as an authorized distributor of record for Citius Oncology providing specialty pharmaceutical distribution services.
Read the full article here. -----
(Nasdaq: CTXR) Recap - 5 Potential Catalysts Lead The Way!
#1. A Low Float Could Create A Volatility Storm Quickly.
#2. Final Preparations Are In Process For A U.S. LYMPHIR Launch In 2H 2025.
#3. The Company's Subsidiary Deploys An Innovative AI Platform Ahead Of LYMPHIR's Anticipated Launch.
#4. A Distribution Expansion Agreement Could Prove Fruitful As Commercialization Nears.
#5. A Distribution Services Agreement With Cardinal Health Marks A Key Step Forward Towards Commercialization. -----
We're officially kicking-off coverage on Biopharma profile Citius Pharmaceuticals, Inc. (Nasdaq: CTXR).
When updates pop up, I'll get them out to you quickly. Talk shortly.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 10/15/2025 and ending on 10/16/2025 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (CTXR:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/ctxr-jqufu/#details | 
